12 results on '"Tang, Wentao"'
Search Results
2. Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression
- Author
-
Liu, Yu, Tang, Wentao, Ren, Li, Liu, Tianyu, Yang, Meng, Wei, Ye, Chen, Yijiao, Ji, Meiling, Chen, Guosong, Chang, Wenju, and Xu, Jianmin
- Published
- 2022
- Full Text
- View/download PDF
3. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases
- Author
-
Jian, Mi, Ren, Li, He, Guodong, Lin, Qi, Tang, Wentao, Chen, Yijiao, Chen, Jingwen, Liu, Tianyu, Ji, Meiling, Wei, Ye, Chang, Wenju, and Xu, Jianmin
- Published
- 2020
- Full Text
- View/download PDF
4. Intratumor APOL3 delineates a distinctive immunogenic ferroptosis subset with prognosis prediction in colorectal cancer.
- Author
-
Lv, Yang, Zheng, Peng, Mao, Yihao, Xu, Yuqiu, Chang, Wenju, Lin, Qi, Ji, Meiling, Ye, Lechi, Tang, Wentao, and Xu, Jianmin
- Abstract
With the essential role of lipid transporting signaling in cancer‐related immunity, apolipoprotein L3 (APOL3), a member of the apolipoprotein L gene family, demonstrated significant modulation ability in immunity. However, the expression profile and critical role of APOL3 in colorectal cancer (CRC) remain unclear. This study aimed to investigate the prognostic significance of APOL3 expression and its biological predictive value in CRC. The study enrolled multiple cohorts, consisting of 911 tumor microarray specimens of CRC patients from Zhongshan Hospital, 412 transcriptional data from The Cancer Genome Atlas, and 30 single‐cell RNA sequencing (scRNA‐seq) from internal and external CRC patients. APOL3 mRNA expression was directly acquired from public datasets, and APOL3 protein expression was detected using immunohistochemistry. Finally, the associations of APOL3 expression with clinical outcomes, immune context, and genomic and ferroptotic features were analyzed. Low APOL3 expression predicted poor prognosis and inferior responsiveness to 5‐fluorouracil‐based adjuvant chemotherapy (ACT) and targeted therapy. APOL3 fosters an immune‐active microenvironment characterized by the promotion of ferroptosis, downregulation of macrophages, and upregulation of CD8+ T cell infiltration. Moreover, the expression of APOL3 in CD8+ T cells is intrinsically linked to ferroptosis and immune activation in CRC. In summary, APOL3 serves as an independent prognosticator and predictive biomarker for immunogenic ferroptosis, ACT, and targeted therapy in CRC. Furthermore, the APOL3 signaling activator could be a novel agent alone or in combination with current therapeutic strategies for CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
- Author
-
Tang, Wentao, Hanada, Keigo, Motoo, Yoshiharu, Sakamaki, Hiroyuki, Oda, Takaaki, Furuta, Kazuyuki, Abutani, Hikaru, Ito, Satoru, and Tsutani, Kiichiro
- Subjects
CANCER patients ,MEDICAL technology ,MEDICAL economics ,HEALTH outcome assessment ,MEDICAL care - Abstract
In Japan, the use of comprehensive genomic profiling (CGP) is only available for cancer patients who have no standard of care (SoC), or those who have completed SoC. This may lead to missed treatment opportunities for patients with druggable alterations. In this study, we evaluated the potential impact of CGP testing before SoC on medical costs and clinical outcome in untreated patients with advanced or recurrent biliary tract cancer (BTC), non-squamous non-small cell lung cancer (NSQ-NSCLC), or colorectal cancer (CRC) in Japan between 2022 and 2026. We constructed a decision-tree model reflecting the healthcare environment of Japan, to estimate the clinical outcome and medical costs impact of CGP testing by comparing two groups (with vs without CGP testing before SoC). The epidemiological parameters, detection rates of druggable alterations, and overall survival were collected from literature and claims databases in Japan. Treatment options selected based on druggable alterations were set in the model based on clinical experts' opinions. In 2026, the number of untreated patients with advanced or recurrent BTC, NSQ-NSCLC, and CRC was estimated to be 8600, 32,103, and 24,896, respectively. Compared with the group without CGP testing before SoC, CGP testing before SoC increased druggable alteration detection and treatment rate with matched therapies in all three cancer types. The medical costs per patient per month were estimated to increase with CGP testing before SoC in the three cancer types by 19,600, 2900, and 2200 JPY (145, 21, and 16 USD), respectively. Only those druggable alterations with matched therapies were considered in the analysis model, while the potential impact of other genomic alterations provided by CGP testing was not considered. The present study suggested that CGP testing before SoC may improve patient outcomes in various cancer types with a limited and controllable increase in medical costs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The m6A RNA Modification Quantity and the Prognostic Effect of Reader YTHDC2 in Colorectal Cancer.
- Author
-
Liu, Tianyu, Tang, Wentao, Chen, Yijiao, Liu, Yu, Xu, Donghao, Jiang, Yudong, Zhou, Shizhao, Qin, Xiaorui, Ren, Li, Chang, Wenju, and Xu, Jianmin
- Subjects
- *
RNA physiology , *SEQUENCE analysis , *CONFIDENCE intervals , *WESTERN immunoblotting , *IMMUNOHISTOCHEMISTRY , *PRECIPITIN tests , *COLORECTAL cancer , *GENE expression , *CANCER patients , *CELLULAR signal transduction , *MASS spectrometry , *KAPLAN-Meier estimator , *TUMOR markers , *ADENOSINES , *CARRIER proteins , *PROPORTIONAL hazards models - Abstract
Background: N6-methyladenosine (m6A) modification plays crucial roles in cancers. However, its alteration in colorectal cancer (CRC) is still poorly described. The purpose of this study is to explore the change of m6A modification and the function of m6A binding protein YTHDC2 in CRC. Methods: The global level of m6A modification was detected by mass spectrometry and dot blotting assay. The expression of YTHDC2 was investigated using The Cancer Genome Atlas and using real-time polymerase chain reaction (RT-qPCR), western blotting, and immunohistochemistry based on CRC tissues. Kaplan–Meier analysis and Cox proportional hazards regression were performed to analyze the prognostic value of YTHDC2. RNA immunoprecipitation (RIP)-seq and m6A immunoprecipitation (MeRIP)-seq were used to explore the direct targets of YTHDC2. Gene oncology (GO) and Gene Set Enrichment Analysis (GSEA) were used to explore the pathways that could be influenced by YTHDC2. Results: No significant difference was observed in the global level of m6A modification on total RNA or mRNA between CRC and adjacent nontumor tissues. We further found a significant decreasing of YTHDC2 in CRC tissues. Kaplan–Meier analysis indicated that lower expression of YTHDC2 was related to the worse disease-free survival and overall survival. In addition, lower expression of YTHDC2 was an independent worse prognostic factor in univariate and multivariate Cox regression analysis. Using YTHDC2-RIP-seq and MeRIP-seq, we identified that YTHDC2 could participate in several important biological signal pathways. Conclusions: In summary, this study suggested that the global level of m6A did not change in CRC and identified that lower YTHDC2 as a prognostic marker for worse survival of CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.
- Author
-
Xu, Donghao, Liu, Yu, Tang, Wentao, Xu, Lingsha, Liu, Tianyu, Jiang, Yudong, Zhou, Shizhao, Qin, Xiaorui, Li, Jisheng, Zhao, Jiemin, Ye, Lechi, Chang, Wenju, and Xu, Jianmin
- Subjects
COLORECTAL cancer ,REGORAFENIB ,METASTASIS ,APOPTOSIS ,PROGRESSION-free survival - Abstract
Background: Regorafenib improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib in the third- or late-line setting for mCRC in four centers in China. Patients and Methods: Patients with refractory mCRC in four centers in China administered regorafenib from February 1, 2018 to June 31, 2021 were enrolled. Patients were grouped into 3 cohorts, namely, the monotherapy (regorafenib alone), chemo (regorafenib plus chemotherapy), and immune [regorafenib plus anti-PD1 (programmed cell death 1) antibodies] groups. Demographic, clinical, survival and safety data were retrospectively analyzed. Results: A total of 177 patients were included in this study. Of them, 116 (65.5%) were treated with regorafenib alone, while 28 (15.9%) and 33 (18.6%) were administered regorafenib plus chemotherapy and anti-PD1 antibodies, respectively. The median followed-up time was 9.2 months. The disease control rate (DCR) was 40.7%. The median PFS (mPFS) was 2.43 months and the median OS (mOS) was 12.2 months. The immune group had longer median PFS (3.5 m vs. 2.2 m, p = 0.043) compared with the monotherapy group. Patients administered regorafenib plus chemotherapy had longer median OS (15.9 m vs. 8.4 m, p = 0.032) compared with the monotherapy group. Patients who began regorafenib treatment at 120 mg had longer median PFS and OS compared with those who began at 80 mg (PFS: 3.7 m vs. 2.0 m; p <0.001; OS: 13.4 m vs. 10.2 m; p = 0.005). Patients with a final dose of 120 mg had longer median PFS and OS compared with the 80 mg or less group (PFS: 5.0 m vs. 2.3 m; p = 0.045; OS: UR (unreach) vs. 10.9 m; p = 0.003). There were 87.0% (154/177) patients who experienced AEs. Three groups had similar rates of AEs (86.2% vs. 89.3% vs. 87.9%; p = 0.89). Conclusion: Patients administered regorafenib alone or regorafenib in combination with other agents were relieved to some extent, with a disease control rate of 40.7%. Regorafenib plus anti-PD1 antibodies showed better PFS, while regorafenib plus chemotherapy had the most benefit in OS. There was no significant difference among three groups in terms of AEs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Anatomical Resection Improves Disease-Free Survival After Lung Metastasectomy of Colorectal Cancer.
- Author
-
Liu, Tianyu, Chang, Wenju, Wang, Hao, Lin, Qi, Wei, Ye, Tang, Wentao, Liu, Yu, Chen, Yijiao, Niu, Zhengchuan, Jiang, Yudong, Ren, Li, and Xu, Jianmin
- Subjects
PROGRESSION-free survival ,COLORECTAL cancer ,PROPORTIONAL hazards models ,METASTASECTOMY ,CHEST endoscopic surgery ,OVERALL survival - Abstract
Purpose: This study aimed to evaluate the role of anatomical resection (AR) in lung metastasectomy (LM) of colorectal cancer (CRC) and to investigate clinically relevant prognostic factors. Patients and Methods: The medical records of 350 consecutive patients who underwent LM of CRC from 2011 to 2019 were reviewed. The patients were designated into AR group (lobectomy and segmentectomy), and non-anatomical resection (NAR) group (wedge resection), respectively. Kaplan–Meier method was used to analyze disease-free survival (DFS), pulmonary-specific disease-free survival (PDFS) and overall survival (OS). Cox proportional hazards regression model was performed to analyze the factors associated with DFS, PDFS and OS. Results: A total of 92 (31.2%) patients were enrolled in AR group and 203 (68.8%) in non-anatomical resection (NAR) group. AR significantly improved the 3-year DFS (64.1% vs 46.8%, HR 0.587, 95% CI 0.397– 0.867, P = 0.007) and PDFS (75.0% vs 60.1%, HR 0.565, 95% CI 0.356– 0.899, P = 0.016) compared with NAR. However, the extent of resection did not significantly impact the 3-year OS (AR 92.4% vs NAR 85.7%, HR 0.511, 95% CI 0.224– 1.165, P = 0.110). In multivariate analysis, AR was identified as a protective factor for DFS (HR 0.576, 95% CI 0.356– 0.934, P = 0.025) and PDFS (HR 0.631, 95% CI 0.409– 0.973, P = 0.037). Preoperative abnormal CA19-9 was identified as the only prognostic factor for OS. Conclusion: AR was superior to NAR for DFS and PDFS after LM from CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Small Nuclear Ribonucleoprotein Polypeptide N Accelerates Malignant Progression and Poor Prognosis in Colorectal Cancer Transcriptionally Regulated by E2F8.
- Author
-
Ji, Meiling, Ren, Li, Lv, Yang, Lao, Xinyuan, Feng, Qingyang, Tang, Wentao, Zhuang, Aobo, Liu, Tianyu, Zheng, Peng, and Xu, Jianmin
- Subjects
COLORECTAL cancer ,PHASE transitions ,CANCER prognosis ,FACTOR analysis ,BIOMARKERS - Abstract
Colorectal cancer is a major cause of death worldwide, and the identification of new diagnostic and prognostic biomarkers is crucial to develop new strategies to avoid colorectal cancer-related deaths. Small nuclear ribonucleoprotein polypeptide N (SNRPN) is an imprinted gene that plays an important role in various neurodevelopmental disabilities. In this study, SNRPN was highly expressed in colorectal cancer tissues and involved in the progression of this disease. Immunohistochemistry analysis of 1,310 colorectal cancer tissue samples showed that SNRPN highly expressed in cancer tissues than in adjacent tissues and was mainly localized in the nucleus. Clinical pathological factor analysis demonstrated that higher expression of SNRPN was significantly associated with larger tumor size, location of the tumor on the left-sided colon, neural invasion, and distant metastasis. Univariate and multivariate analyses showed that SNRPN expression was an independent risk factor for survival, with high expression levels indicating worse overall survival. Both in vitro and in vivo experiments confirmed that high expression of SNRPN was associated with tumor proliferation, cell cycle, and metastasis. Knocking down SNRPN blocked the cell cycle at the G2/M phase transition and promoted tumor cell apoptosis, inhibiting the progression of colorectal cancer. To explore the up-steam of SNRPN, we found by luciferase reporter assay and chromosomal immunoprecipitation assay that E2F8 was a transcriptional regulator up-steam of SNRPN in colorectal cancer. Systematic studies of SNRPN will help us discover new regulatory molecules and provide a theoretical basis for finding new molecular targets for this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
- Author
-
Chen, Yijiao, Chang, Wenju, Ren, Li, Chen, Jingwen, Tang, Wentao, Liu, Tianyu, Jian, Mi, Liu, Yu, Wei, Ye, and Xu, Jianmin
- Subjects
LIVER surgery ,DISEASE relapse ,CANCER patients ,COLON tumors ,EXPERIMENTAL design ,LIVER tumors ,MATHEMATICAL models ,RESEARCH methodology ,METASTASIS ,PROGNOSIS ,RECTUM tumors ,RISK assessment ,THEORY ,PROPORTIONAL hazards models ,RESEARCH methodology evaluation - Abstract
Background: The calculation of the tumor burden score (TBS) is not perfect because the bilobar spread of colorectal liver metastasis (CRLM) is neglected. The identification of an ideal prognostic scoring system for CRLM remains controversial. Materials and Methods: Patients who underwent curative intent liver resection for CRLM from one medical center were enrolled in cohort 1 (787 patients) and cohort 2 (162 patients). Tumor relapse‐free survival (RFS) was the main outcome. A Cox regression model was used to identify independent predictors of prognosis. The time‐dependent area under the curve, calibration curve, and C‐index were employed to validate the predictive ability of the survival model. Results: Modified TBS (mTBS) was established by a mathematical equation with parameters including CRLM size, CRLM number, and unilobar or bilobar metastasis. Five preoperative predictors of worse RFS were identified in cohort 1 and incorporated into the Comprehensive Evaluation of Relapse Risk (CERR) score: KRAS/NRAS/BRAF‐mutated tumor (1 point); node‐positive primary (1 point); extrahepatic disease (1 point); carcinoembryonic antigen level > 200 ng/mL or carbohydrate antigen 19‐9 (CA19‐9) >200 U/mL (1 point); and mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients in cohort 1 were stratified by their CERR score into risk groups: the high‐risk group (CERR score 4 or more), the medium‐risk group (CERR score 2–3), and the low‐risk group (CERR score 0–1). Importantly, internal validation in cohort 1 and further validation in cohort 2 both showed the superior discriminatory capacity of the CERR score. Conclusion: mTBS should be promoted. The CERR score is a powerful prognostic tool that can help determine optimal clinical management strategies. Implications for Practice: This work resulted in the successful modification of the tumor burden score and development of a comprehensive and practical prognostic scoring system—the Comprehensive Evaluation of Relapse Risk (CERR) score. The CERR score, with a better prognostic discriminatory ability, outperformed the Fong score. Perhaps more importantly, the CERR score is a powerful prognostic tool because it unified the most consistently reported prognostic factors. Therefore, the CERR score can assist doctors in determining optimal clinical management strategies. The tumor burden score (TBS) is a prognostic indicator of the cumulative effect of tumor size and tumor number on survival; however, the score is not perfect because bilobar spread of colorectal liver metastases (CRLM) is neglected. This article reports a modified TBS that unifies three parameters (CRLM size, CRLM number, and unilobar/bilobar metastasis) and development of a more comprehensive and practical prognostic scoring system—the Comprehensive Evaluation of Relapse Risk (CERR) score. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
- Author
-
Xu, Yuqiu, Wang, Guiying, Zheng, Xuzhi, Chang, Wenju, Fu, Jihong, Zhang, Tao, Lin, Qi, Lv, Yang, Zhu, Zhehui, Tang, Wentao, and Xu, Jianmin
- Subjects
COLORECTAL cancer ,BRAF genes ,METASTASIS ,OVERALL survival ,PROGRESSION-free survival - Abstract
BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time. Treatment approaches vary depending on whether or not the metastases are initially resectable. The benefit of metastasectomy remains unclear, and the optimal first-line treatment is controversial. This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the recurrence pattern in resectable patients, and explore the optimal first-line treatment for unresectable patients. Patients diagnosed with BRAF V600E mutant-mCRC between February 2014 and January 2022 in five hospitals were enrolled. Date on clinical and pathological characteristics, treatment features, and survival outcomes were collected. Of the 220 included patients, 64 initially resectable patients had a significantly longer overall survival (OS) (37.07 vs. 20.20 months, P < 0.001) than initially unresectable patients. Of 156 unresectable patients, 54 received doublet (FOLFOX, XELOX or FOLFIRI) or triplet (FOLFOXIRI) chemotherapies (Chemo), 55 received Chemo plus Bevacizumab (Chemo+Bev), and 33 received vemurafenib plus cetuximab and irinotecan (VIC). The VIC regimen had a better progression-free survival (PFS) (12.70 months) than the Chemo (6.70 months, P < 0.001) and Chemo+Bev (8.8 months, P = 0.044) regimens. Patients treated with VIC had the best overall response rate (60.16%, P < 0.001), disease control rate (93.94%, P < 0.001) and conversional resection rate (24.24%, P = 0.003). Metastasectomy is beneficial to the survival of patients with BRAF V600E mutant-mCRC. For initially unresectable patients, VIC as first-line therapy is associated with a better prognosis and efficacy than doublet and triplet chemotherapy with or without bevacizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
- Author
-
Lin, Qi, Ding, Kefeng, Zhao, Ren, Wang, Hao, Wei, Ye, Ren, Li, Ye, Qinghai, Cui, Yuehong, He, Guodong, Tang, Wentao, Feng, Qingyang, Zhu, Dexiang, Chang, Wenju, Wang, Xiaoying, Liang, Li, Zhou, Guofeng, Liang, Fei, Ye, Feng, Wang, Jianwei, and Fan, Jia
- Subjects
- *
PREOPERATIVE care , *RESEARCH , *CANCER chemotherapy , *METASTASIS , *SURGICAL complications , *COLORECTAL cancer , *RANDOMIZED controlled trials , *PRE-tests & post-tests , *COMPARATIVE studies , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *STATISTICAL sampling - Abstract
Primary tumour resection (PTR) is still a selection for patients with low tumour burden and good condition, especially with conversion therapy purpose for colorectal liver-limited metastases (CRLMs). The objective was to evaluate whether pre-PTR chemotherapy could improve progression-free survival (PFS) for patients with asymptomatic synchronous unresectable CRLMs. Patients with asymptomatic synchronous unresectable CRLMs were randomly assigned to receive pre-PTR chemotherapy (arm A) or upfront PTR (arm B). Chemotherapy regimens of mFOLFOX6 plus cetuximab, mFOLFOX6 plus bevacizumab or mFOLFOX6 alone were chosen according to the RAS genotype. The primary end-point was PFS; secondary end-points included overall survival (OS), tumour response, disease control rate (DCR), liver metastases resection rate, surgical complications and chemotherapy toxicity. Three hundred and twenty patients were randomly assigned to arm A (160 patients) and arm B (160 patients). Patients in arm A had significantly improved the median PFS compared with arm B (10.5 versus 9.1 months; P = 0.013). Patients in arm A also had significantly better DCR (84.4% versus 75.0%; P = 0.037). The median OS (29.4 versus 27.2 months; P = 0.058), objective response rate (ORR) (53.1% versus 45.0%; P = 0.146) and liver metastases resection rate (21.9% versus 18.1%; P = 0.402) were not significantly different. The Clavien–Dindo 3–4 complications post PTR (4.5% versus 3.8%, P = 0.759) and the incidence of grade 3/4 chemotherapy events (42.2% versus 40.4%, P = 0.744) reached no statistical significance. For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR. • It was the first RCT to evaluate the PFS of pre-PTR chemotherapy for CRLMs. • Pre-PTR chemotherapy improved the PFS compared with upfront PTR. • This trial provided evidence to confirm the advantages of pre-PTR chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.